TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial

To date, there is no approved local therapeutic agent for the treatment of epistaxis due to hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use of timolol. This monocentric, prospective, randomized, placebo-controlled, double-blinded, cross-over study investigat...

Descripción completa

Detalles Bibliográficos

Autores principales:	Kornelia E. C. Andorfer, Florian Zeman, Michael Koller, Judith Zeller, René Fischer, Caroline T. Seebauer, Veronika Vielsmeier, Christopher Bohr, Thomas S. Kühnel
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-10-01
Colección:	Pharmaceutics
Materias:	timolol nasal spray HHT hereditary hemorrhagic telangiectasia Morbus Osler orphan disease
Acceso en línea:	https://www.mdpi.com/1999-4923/14/11/2335
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!